Serum Institute Expects WHO Emergency Approval for Oxford-AstraZeneca Covid-19 Vaccine Shot Soon
3 years, 11 months ago

Serum Institute Expects WHO Emergency Approval for Oxford-AstraZeneca Covid-19 Vaccine Shot Soon

News 18  

The Serum Institute of India expects WHO emergency-use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for mid and low income countries, its chief executive said. “The emergency use licensure from the WHO should be available and coming through in the next week or two, hopefully, because we have submitted everything,” Adar Poonawalla told the Reuters Next conference on Thursday. Poonawalla also said his company, the world’s biggest vaccine maker, would start stockpiling millions of doses of the Novavax coronavirus vaccine candidate from around April. The Serum Institute CEO said a special purpose vehicle housing its pandemic-related products should be valued at $12 billion to $13 billion.

Serum Institute  emergency  billion  vaccine  worlds  institute  coronavirus  world  saidthe  doses  expects  covid19  novavax  approval  soon  serum  oxfordastrazeneca  shot

History of this topic

Global vaccine alliance GAVI to buy 500,000 doses of mpox vaccine
3 months, 3 weeks ago

Global vaccine alliance GAVI to buy 500,000 doses of mpox vaccine

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy The global vaccine alliance Gavi …

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official
8 months ago

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official

News 18  

AstraZeneca’s vaccine has demonstrated the lowest incidence of side effects in India compared to the global average, a top government official involved in the national roll-out of Covid-19 vaccination told News18. “But only around 50 cases witnessed Thrombosis with Thrombocytopenia Syndrome — a rare side effect caused by the jab — of the 180 crore doses administered against 4 to …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
8 months ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

Stopped manufacturing Covishield since December 2021, says Serum Institute
8 months ago

Stopped manufacturing Covishield since December 2021, says Serum Institute

Hindustan Times  

Pune-based Serum Institute of India stopped manufacturing its anti-Covid-19 vaccine Covishield in 2021, according to a statement issued by the company on Wednesday after British-Swedish pharmaceutical manufacturer AstraZeneca announced it was withdrawing its vaccine against Covid, Vaxzevria, due to “commercial reasons” as demand for it decreased globally. Consequently, since December 2021, we have stopped the manufacturing and supply of additional …

AstraZeneca pulls its COVID-19 vaccine from the European market
8 months ago

AstraZeneca pulls its COVID-19 vaccine from the European market

Associated Press  

LONDON — The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator. In an update on the European Medicines Agency’s website Wednesday, the regulator said that the approval for AstraZeneca’s Vaxzevria had been withdrawn “at the request of the marketing authorization holder.” AstraZeneca’s COVID-19 vaccine was first given …

Now you'll be able to pay for a Covid vaccine privately! Chemists will sell top-up jabs to anyone for £45 under major shake-up of roll-out scheme
11 months, 1 week ago

Now you'll be able to pay for a Covid vaccine privately! Chemists will sell top-up jabs to anyone for £45 under major shake-up of roll-out scheme

Daily Mail  

Chemists will start offering Covid vaccines privately, with Brits able to buy them for as little as £45 within weeks. Although Pharmadoctor said it will expand its catalogue 'as more vaccines become licensed for the private market' Uptake for the autumn booster roll-out stood at around 68.8 per cent. A 2022 study led by academics at Imperial College London suggests …

Novavax’s COVID-19 vaccine gets the green light from the FDA, giving third option for protection
1 year, 3 months ago

Novavax’s COVID-19 vaccine gets the green light from the FDA, giving third option for protection

Salon  

On Tuesday, the Food and Drug Administration authorized the use of a new Novavax vaccine specifically targeted to protect against the latest Omicron circulating strains. Following a bumpy rollout of the Moderna and Pfizer vaccines, it will bring another option to the table for those who are ready to roll up their sleeves and get vaccinated amid a rise in …

India-made mRNA vaccine priced at ₹2,292, will be available as a booster dose
1 year, 6 months ago

India-made mRNA vaccine priced at ₹2,292, will be available as a booster dose

The Hindu  

India’s first indigenously developed mRNA vaccine against the dominant Omicron variant of the COVID-19 coronavirus will cost ₹2,292, Sanjay Singh, CEO, Gennova Biopharmaceuticals, said at a press conference on June 24. The vaccine will for now only be available as a booster or “precaution dose”, that is, somebody who has already been vaccinated thrice will be ineligible as the relevant …

Axed Covid vaccine contract cost taxpayers £358m
1 year, 6 months ago

Axed Covid vaccine contract cost taxpayers £358m

The Independent  

Get the free Morning Headlines email for news from our reporters across the world Sign up to our free Morning Headlines email Sign up to our free Morning Headlines email SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy A biotechnology company which had its contract to make Covid …

COVID-19 vaccine maker Novavax to chop workforce, expenses
1 year, 8 months ago

COVID-19 vaccine maker Novavax to chop workforce, expenses

Associated Press  

Novavax is cutting about a quarter of its global workforce as the COVID-19 vaccine maker seeks to slash expenses while dealing with uncertain future revenue. The company said Tuesday that it expects to trim next year’s costs for research and development as well as selling, general and administrative expenses by about 40% to 50% compared to 2022. A Novavax representative …

Serum Institute to double investment in Biocon’s unit to $300 million
1 year, 8 months ago

Serum Institute to double investment in Biocon’s unit to $300 million

Live Mint  

As part of its expansion of investment in one of Biocon Ltd's units, Serum Institute of Life Sciences will give it access to 100 million vaccine doses annually. As per the new alliance, the company would pump in $150 million after converting a loan to Biocon Pharma Limited into equity in Biocon Biologics Ltd. The investment made is in addition …

Serum Institute of India to produce 5mn Covishield doses in two months
1 year, 8 months ago

Serum Institute of India to produce 5mn Covishield doses in two months

Hindustan Times  

Serum Institute of India chief executive officer Adar Poonawalla, while underlining that the current strain of Covid is mild and the demand for vaccine shots is low, said his firm will produce five to six million Covishield doses in the next two to three months and same amount of stock is already available for Covovax. According to Poonawalla, SII has …

AstraZeneca expects ‘minimal’ sales of Covid vaccine this year
1 year, 11 months ago

AstraZeneca expects ‘minimal’ sales of Covid vaccine this year

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. A year earlier the business sold 1.8 billion US …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
2 years ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses
2 years ago

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses

News 18  

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of Covid-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses
2 years ago

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses

Live Mint  

The two major Hyderabad-based vaccine manufacturing units, Biological E and Bharat Biotech, together are holding about 250 million Covid vaccine doses ready to dispatch as and when orders are received, according to news agency PTI. Currently, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
2 years ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here
2 years ago

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here

Live Mint  

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above according to reports will be available at ₹800+ GST+ hospital charges according to sources. The country’s first intranasal covid vaccine will be rolled out in the fourth week of January as a booster dose for those …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

How Pfizer plans to sell its Covid vaccine back to YOU with a 10,000% markup
2 years, 2 months ago

How Pfizer plans to sell its Covid vaccine back to YOU with a 10,000% markup

Daily Mail  

Pfizer has been accused of 'daylight robbery' after it emerged the company plans to sell its Covid shot with an estimated 10,000 percent markup in the US next year — despite enjoying extraordinary surges in profits during the pandemic. Dr Ugur Sahin, the brains behind the Covid shot and CEO of Pfizer's German partner BioNTech, is among nine 'vaccine billionaires' …

GAVI financing to allow for immediate funds for next pandemic
2 years, 3 months ago

GAVI financing to allow for immediate funds for next pandemic

Live Mint  

Global vaccine alliance GAVI has set up financial instruments that will allow the group to immediately access pledged donor funding if it needs to buy vaccines for future pandemics, Chief Executive Seth Berkley told Reuters. Berkley said that in 2020 and 2021, GAVI was limited in its ability to buy COVID-19 vaccines because even though donors had committed $2.4 billion, …

Serum Institute Will Try to Launch Omicron-specific Covid-19 Vaccine After Six Months, Says Adar Poonawalla
2 years, 4 months ago

Serum Institute Will Try to Launch Omicron-specific Covid-19 Vaccine After Six Months, Says Adar Poonawalla

News 18  

The Serum Institute of India will try to launch Omicron-specific vaccine for COVID-19 after six months, its CEO Adar Poonawalla said on Thursday. “The original Novovax vaccine Covovax covers omicron and there is good data for it. We will try to launch Omicron-specific vaccine after six months,” he said. The Pune-based Serum Institute is working with US biotechnology major Novavax …

US regulators OK new COVID-19 shot option from Novavax
2 years, 5 months ago

US regulators OK new COVID-19 shot option from Novavax

Associated Press  

The U.S. is getting another COVID-19 vaccine choice as the Food and Drug Administration on Wednesday cleared Novavax shots for adults. Novavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S. -- and one that’s already available in Europe and multiple other countries. Novavax also has submitted data on booster …

COVID-19: US FDA authorises Novavax vaccine for emergency use in adults
2 years, 5 months ago

COVID-19: US FDA authorises Novavax vaccine for emergency use in adults

India TV News  

Highlights US regulators OK new COVID-19 shot option from Novavax vaccine Food and Drug Administration on Wednesday cleared Novavax shots for adults in US Novavax makes more traditional type of shot than three other COVID vaccines available for use in US COVID-19 news : The US is getting another COVID-19 vaccine choice as the Food and Drug Administration on Wednesday …

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US
2 years, 6 months ago

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US

India Today  

The government has allowed Serum Institute of India to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported to the country by any Indian manufacturer, official sources said on Friday. "It is a matter of pride for us and our country that, in …

FDA advisers back Novavax COVID-19 shots as fourth US option
2 years, 7 months ago

FDA advisers back Novavax COVID-19 shots as fourth US option

Firstpost  

The FDA advisory panel voted that the benefits of two primary Novavax doses outweigh its risks — but they had a lot of questions about the shots’ role at this point in the pandemic. Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation’s fourth coronavirus shot for adults. FDA’s vaccine chief …

FDA advisers back Novavax COVID shots as 4th US option
2 years, 7 months ago

FDA advisers back Novavax COVID shots as 4th US option

Associated Press  

American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot. Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation’s fourth coronavirus shot for adults. FDA’s vaccine chief Dr. Peter Marks …

FDA advisory panel gives near-unanimous recommendation to Novavax's COVID-19 vaccine
2 years, 7 months ago

FDA advisory panel gives near-unanimous recommendation to Novavax's COVID-19 vaccine

Daily Mail  

Novavax's COVID-19 vaccine received near-unanimous approval for use in adults over 18 years old on Tuesday, paving the way for it to become the fourth jab and first protein-based shot to be rolled out in America. Unlike Pfizer and Moderna's shots, the Novavax jab uses the same protein-based technology as flu vaccines, which expose the immune system to spike proteins …

Advisers to the FDA back Novavax COVID vaccine
2 years, 7 months ago

Advisers to the FDA back Novavax COVID vaccine

NPR  

Advisers to the FDA back Novavax COVID vaccine Enlarge this image toggle caption Karen Ducey/Getty Images Karen Ducey/Getty Images In a 21-0 vote with one abstention, advisers to the Food and Drug Administration recommended that the agency authorize Novavax's two-dose vaccine against COVID-19. In comments to the committee before its vote, Dr. Peter Marks, the FDA's top vaccine official said, …

FDA advisors back Novavax COVID-19 vaccine as a new U.S. option
2 years, 7 months ago

FDA advisors back Novavax COVID-19 vaccine as a new U.S. option

LA Times  

American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisors to the Food and Drug Administration on Tuesday backed a more traditional type of shot. Next, the FDA must decide whether to authorize the vaccine made by latecomer Novavax, a protein vaccine that’s made with a more conventional tech- nology than today’s U.S. options. …

Novavax hopes its COVID shot wins over FDA, vaccine holdouts
2 years, 7 months ago

Novavax hopes its COVID shot wins over FDA, vaccine holdouts

Associated Press  

— Americans may soon get a new COVID-19 vaccine option -- shots made with a more tried-and-true technology than today’s versions. “What I’ve seen of the Novavax data so far is it’s a really impressive protein vaccine,” said University of Pennsylvania immunologist E. John Wherry. Novavax, a small biotech company, created the vaccine in its research lab, but the Serum …

Q&A: Novavax hopes its COVID shot wins over FDA, vaccine holdouts
2 years, 7 months ago

Q&A: Novavax hopes its COVID shot wins over FDA, vaccine holdouts

LA Times  

Americans may soon get a new COVID-19 vaccine option — shots made with a more tried-and-true technology than today’s versions. “What I’ve seen of the Novavax data so far is it’s a really impressive protein vaccine,” said University of Pennsylvania immunologist E. John Wherry. Novavax, a small biotech company, created the vaccine in its research lab, but the Serum Institute …

Pfizer to offer low-cost medicines, vaccines to poor nations
2 years, 7 months ago

Pfizer to offer low-cost medicines, vaccines to poor nations

Associated Press  

Pfizer said Wednesday that it will provide nearly two dozen products, including its top-selling COVID-19 vaccine and treatment, at not-for-profit prices in some of the world’s poorest countries. The drugmaker announced the program at the World Economic Forum’s annual gathering in Davos, Switzerland, and said it was aimed at improving health equity in 45 lower-income countries. “What we discovered through …

Adar Poonawalla’s Pitch for Pandemic Treaty at Davos, Says Might Have to Destroy Covid Jab Doses
2 years, 7 months ago

Adar Poonawalla’s Pitch for Pandemic Treaty at Davos, Says Might Have to Destroy Covid Jab Doses

News 18  

Serum Institute of India chief executive officer Adar Poonawalla, in an interview to Shereen Bhan of CNBC-TV18, on Monday said he is advocating a global pandemic treaty, and has proposed that there should be a framework for leaders to work with. Stressing that there is an “oversupply” of Covid-19 vaccines in the world, Poonawalla, on the sidelines of the World …

Biological E Slashes Price of Corbevax Covid-19 Vaccine to Rs 250 per Dose. Check Details
2 years, 7 months ago

Biological E Slashes Price of Corbevax Covid-19 Vaccine to Rs 250 per Dose. Check Details

News 18  

Biological E on Monday announced reducing the price of each dose its Covid-19 vaccine Corbevax to Rs 250 from Rs 840 at private vaccination centres. In March this year when the inoculation of children in the age group of 12 to 14 years against COVID-19 commenced in the country, Corbevax vaccine was used and its price was fixed at Rs …

With old-school technology, can Novavax win over COVID vaccine skeptics?
2 years, 7 months ago

With old-school technology, can Novavax win over COVID vaccine skeptics?

LA Times  

A vial of the Novavax COVID-19 vaccine is ready for use in a Phase 3 clinical trial in London. Some people “may prefer tried and true technologies” for COVID-19 vaccines, said Dr. Filip Dubovsky, the chief medical officer of Novavax. It’s even possible a single Novavax shot could target multiple coronavirus variants in one shot, although Dubovsky said it makes …

SII Lowers Each Dose of Covovax Jab from Rs 900 to Rs 225 Excluding Taxes
2 years, 8 months ago

SII Lowers Each Dose of Covovax Jab from Rs 900 to Rs 225 Excluding Taxes

News 18  

A day after its Covid shot Covovax was included on the CoWIN portal for inoculation of children aged 12-17 years at private vaccination centres, the Serum Institute of India on Tuesday reduced the price of each dose of the vaccine from Rs 900 to Rs 225, excluding taxes. On Tuesday, Director for Government and Regulatory Affairs, SII, Prakash Kumar Singh, …

UK clears 6th Covid vaccine despite cancelling deal for doses
2 years, 8 months ago

UK clears 6th Covid vaccine despite cancelling deal for doses

India Today  

British authorities have authorized a coronavirus vaccine for adults made by French drugmaker Valneva, despite the government's decision last year to cancel an order for at least 100 million doses. Britain's medicines regulator said Thursday that the two-dose vaccine is intended for adults ages 18 to 50, with the second dose given about a month after the first. FULL CORONAVIRUS …

Dutch gov’t ordered 840,000 Novavax Covid jabs; Only 1,000 shots used
2 years, 8 months ago

Dutch gov’t ordered 840,000 Novavax Covid jabs; Only 1,000 shots used

NL Times  

The Netherlands purchased 840,000 doses of the Novavax vaccine against Covid-19 for approximately 15 million euros, but nobody seems to want the protein-based vaccine. The government purchased the Novavax vaccines as an alternative for people who don't want to get an mRNA vaccine or vector vaccine against the coronavirus because the techniques behind those are still young. But since March …

SII has stockpile of 200 mn doses; India better prepared to fight Covid: CEO
2 years, 8 months ago

SII has stockpile of 200 mn doses; India better prepared to fight Covid: CEO

Hindustan Times  

Chief executive officer of Serum Institute of India Adar Poonawalla on Tuesday said the company has a stockpile of 200 million doses of Covishield, while it has already exported 40 million doses of Covovax to European countries and Australia. Serum Institute of India CEO Adar Poonawalla speaks at the 'AIMA Leadership Conclave' in New Delhi on Tuesday, "We have a …

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference
2 years, 8 months ago

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference

News 18  

A day after slashing the price of the precaution dose of Covishield to Rs 225 per shot for private hospitals, the Serum Institute of India told the Centre on Sunday that it will compensate for the price difference for the unexpired stocks lying with private centres in the form of free vials of fresh stocks, official sources said. Vaccine majors …

Covishield, Covaxin to now cost private hospitals Rs 225 per dose
2 years, 9 months ago

Covishield, Covaxin to now cost private hospitals Rs 225 per dose

India Today  

A single dose of the Serum Institute of India's Covishield and Bharat Biotech's Covaxin will now cost private hospitals Rs 225. Adar Poonawalla, CEO of SII, said in a tweet on Saturday that the vaccine maker has decided to slash the prices of the Covid-19 jab for private hospitals from Rs 600 to Rs 225 after consultation with the central …

Precaution Dose at Rs 225: Prices of Covishield, Covaxin Revised for Private Hospitals. Check Details
2 years, 9 months ago

Precaution Dose at Rs 225: Prices of Covishield, Covaxin Revised for Private Hospitals. Check Details

News 18  

A day ahead of the beginning of the Covid-19 booster dose inoculation to all those above 18 years of age, the Serum Institute of India and Bharat Biotech on Saturday announced to revise the prices of the Covishield and Covaxin vaccines for private hospitals. Welcoming the Centre’s move to allow the precaution dose to all aged above 18 years at …

Covishield booster shots to be priced at ₹600 plus taxes: Adar Poonawalla
2 years, 9 months ago

Covishield booster shots to be priced at ₹600 plus taxes: Adar Poonawalla

Hindustan Times  

The Union health ministry announced on Friday that beginning April 10, booster doses will be available to all adults at private Covid-19 vaccine centres. Soon after, Serum Institute of India CEO Adar Poonawalla said Covishield precautionary for all adults will be priced at ₹600 per shot plus taxes. Meanwhile, Covovax - which has not been formally announced as a booster …

Rich countries getting new COVID vaccine before poorer ones despite U.N.-backed initiative
2 years, 9 months ago

Rich countries getting new COVID vaccine before poorer ones despite U.N.-backed initiative

LA Times  

A worker moves boxes carrying Novavax’s COVID-19 vaccine at SK Bioscience Co. in Andong, South Korea, on Feb. 9. Novavax, the company behind a COVID-19 vaccine touted as a key tool for the developing world, will miss a target for giving doses to a U.N.-backed effort to supply shots to poorer countries. The company behind a COVID-19 vaccine touted as …

Rich Countries Getting New COVID Vaccine Before Poorer Ones
2 years, 9 months ago

Rich Countries Getting New COVID Vaccine Before Poorer Ones

Huff Post  

FILE - A worker moves boxes carrying Novavax's COVID-19 vaccine at SK Bioscience Co. in Andong, South Korea, on Feb. 9, 2022. via Associated Press NEW DELHI — The company behind a COVID-19 vaccine touted as a key tool for the developing world has sent tens of millions of doses to wealthy nations but provided none yet to the U.N.-backed …

Rich countries getting new COVID vaccine before poorer ones
2 years, 9 months ago

Rich countries getting new COVID vaccine before poorer ones

Associated Press  

NEW DELHI — The company behind a COVID-19 vaccine touted as a key tool for the developing world has sent tens of millions of doses to wealthy nations but provided none yet to the U.N.-backed effort to supply poorer countries, a sign that inequity persists in the global response to the pandemic. The company, Novavax, got $388 million from one …

Rich countries getting new Novavax COVID-19 vaccine before poorer ones
2 years, 9 months ago

Rich countries getting new Novavax COVID-19 vaccine before poorer ones

LA Times  

The company behind a COVID-19 vaccine touted as a key tool for the developing world has sent tens of millions of doses to wealthy nations but provided none yet to the United Nations-backed effort to supply poorer countries, a sign that inequity persists in the global response to the pandemic. The investment guaranteed COVAX the “right of first refusal” to …

India's drugs regulator approves phase-3 trial of covid vaccine covovax
2 years, 9 months ago

India's drugs regulator approves phase-3 trial of covid vaccine covovax

India Today  

The Drugs Controller General of India granted permission on Wednesday for conducting the phase-3 clinical trial of Covid-19 vaccine Covovax as a booster dose in adults, official sources said. The Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation had, on March 5, recommended permission for conducting the phase-3 clinical trial for Covovax as a booster dose …

Discover Related